We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.
- Authors
Kim, Hyera; Choi, Ehyun; Heo, Mi Hwa; Kim, Jin Young; Park, Keon Uk
- Abstract
Background: Elderly patients with extensive-disease small-cell lung cancer (ED-SCLC) have a high risk of chemotherapy toxicity due to multiple comorbidities and poor performance status. Although dose modification is often used to avoid toxicity in elderly patients with ED-SCLC, there is little data on the effect of initial dose-reduced chemotherapy on survival outcomes. Methods and Patients: We retrospectively reviewed 100 elderly patients (≥70 years) with ED-SCLC who received first-line etoposide plus platinum chemotherapy between January 2006 and December 2020. Results: The median age was 74 years. Eighty-nine patients (89%) had a history of smoking, and 38 (38%) had chronic lung disease. Thirty-four patients (34%) received dose-reduced etoposide plus platinum in the first cycle. The dose-reduced group had significantly higher age, lower body mass index, and poor Eastern Cooperative Oncology Group Performance Score. There were no significant differences in survival outcomes between the dose-reduced and full-dose chemotherapy (median overall survival [OS], 4.9 vs. 6.5 months, p = 0.440; median progression-free survival [PFS], 3.7 vs. 4.6 months, p = 0.272). In multivariate analyses, DR in the first cycle (hazard ratio 0.519, 95% CI: 0.269–1.000, p = 0.050) was significantly associated with OS. Following a subgroup analysis of 59 patients who received minimum four cycles, no significant differences in survival outcomes between the two groups (median OS, 10.9 vs. 9.4 months, p = 0.817; median PFS, 6.3 vs. 6.5 months, p = 0.902) were noted. Conclusions: The dose-reduced chemotherapy with first-line etoposide plus platinum had non-inferior survival outcomes compared to the full-dose chemotherapy in elderly patients with ED-SCLC.
- Subjects
ETOPOSIDE; DRUG dosage; CONFIDENCE intervals; SMALL cell carcinoma; MULTIVARIATE analysis; LUNG tumors; RETROSPECTIVE studies; PLATINUM; SEVERITY of illness index; TREATMENT effectiveness; DESCRIPTIVE statistics; SMOKING; BODY mass index; DRUG toxicity; OLD age
- Publication
Oncology, 2022, Vol 100, Issue 6, p313
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000524476